Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin A David

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer Biology & Therapy|March 5, 2010
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignanciesKevin A David, Nigel P Mongan, Christopher Smith, et al.
British Journal of Haematology|August 28, 2019
Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphomaFrank C Passero, Dashnamoorthy Ravi, J Tyson McDonald, et al.
Cancer|February 14, 2009
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000Kevin A David, Katherine Mallin, Matthew I Milowsky, et al.
Clinical Genitourinary Cancer|May 30, 2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David, Matthew I Milowsky, Lale Kostakoglu, et al.
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Frontiers in Oncology|November 12, 2021
Oncogenic Integration of Nucleotide Metabolism <i>via</i> Fatty Acid Synthase in Non-Hodgkin LymphomaDashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern eraAndrew M Evens, Kevin A David, Irene Helenowski, et al.
Leukemia & Lymphoma|May 3, 2022
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCLDeborah A Katz, Joan D Morris, Michael P Chu, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer Biology & Therapy|March 5, 2010
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignanciesKevin A David, Nigel P Mongan, Christopher Smith, et al.
British Journal of Haematology|August 28, 2019
Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphomaFrank C Passero, Dashnamoorthy Ravi, J Tyson McDonald, et al.
Cancer|February 14, 2009
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000Kevin A David, Katherine Mallin, Matthew I Milowsky, et al.
Clinical Genitourinary Cancer|May 30, 2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David, Matthew I Milowsky, Lale Kostakoglu, et al.
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Frontiers in Oncology|November 12, 2021
Oncogenic Integration of Nucleotide Metabolism <i>via</i> Fatty Acid Synthase in Non-Hodgkin LymphomaDashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern eraAndrew M Evens, Kevin A David, Irene Helenowski, et al.
Leukemia & Lymphoma|May 3, 2022
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCLDeborah A Katz, Joan D Morris, Michael P Chu, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Pageof 4